TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00979342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic Morcellator
Description: The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic Morcellator
Description: The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
Study: NCT04905004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canine retraction
Description: Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Canine retraction
Description: Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canine retraction
Description: Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canine retraction
Description: Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.
Study: NCT02671435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Participants will receive IV infusion of monalizumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.
Study: NCT01945411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the length between incisor and mandible angle
Description: the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the length between mouth corner-mandible angle
Description: the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
Study: NCT00350363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zymar
Description: zymar qid
Study: NCT04599959

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol
Description: Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
Study: NCT03618732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral movement-based computer training
Study: NCT02671435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.
Study: NCT03618732

Intervention type: OTHER
Group type: OTHER
Intervention: Video-directed conventional training
Study: NCT04049266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal Injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study: NCT02671435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.
Study: NCT02579044

Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus and lonafarnib
Study: NCT02671435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants will receive IV infusion of cetuximab as stated in arm description.
Study: NCT02093845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix NeoFlex coronary stent
Description: Percutaneous coronary intervention involving use of stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNERGY stent
Description: Percutaneous coronary intervention involving use of stent
Study: NCT03944954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo TMS Sham
Description: Individuals will receive placebo dose and sham TMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo TMS Sham
Description: Individuals will receive placebo dose and sham TMS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marinol 10Mg Capsule TMS Sham
Description: Individuals will receive 10mg dose and sham TMS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marinol 10Mg Capsule TMS Sham
Description: Individuals will receive 10mg dose and sham TMS.
Study: NCT03215992

Intervention type: DEVICE
Group type: OTHER
Intervention: Diffuse Optical Tomography (DOT) System
Description: Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
Study: NCT03944954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marinol 30Mg Capsule TMS Sham
Description: Individuals will receive 30mg dose and sham TMS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marinol 30Mg Capsule TMS Sham
Description: Individuals will receive 30mg dose and sham TMS.
Study: NCT02671435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants will receive IV infusion of cetuximab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants will receive IV infusion of cetuximab as stated in arm description.
Study: NCT03944954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo TMS Real
Description: Individuals will receive placebo and real TMS.
Study: NCT02671435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants will receive IV infusion of cetuximab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants will receive IV infusion of cetuximab as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Participants will receive IV infusion of mFOLFOX as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Participants will receive IV infusion of mFOLFOX as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive IV infusion of bevacizumab as stated in arm description.
Study: NCT03252886

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
Study: NCT03433833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin oral route once daily for 24 weeks.
Study: NCT03240367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coutery
Description: Stapler line bleeding control with coutery
Study: NCT02309645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVICEL® Fibrin Sealant
Description: Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.

Intervention type: OTHER
Group type: OTHER
Intervention: Sutures Only
Description: Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
Study: NCT00555763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tonometry
Description: Tonometry : measurement of intraocular pressure with an applanation tonometer
Study: NCT03092830

Intervention type: GENETIC
Intervention: Molecular testing of DNA/RNA from skin tumors, SCC/BCC
Description: Molecular testing of DNA/RNA from skin tumors, SCC/BCC
Study: NCT03006848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: To assess quality of life, patients will complete questionnaires at four time points.
Study: NCT05559840

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S-Condom Uterine Tamponade
Description: The condom catheter will be inflated with air

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional condom catheter
Description: The condom catheter will be inflated with saline following national protocol
Study: NCT03484507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: 1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: 1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Sodium Phosphate
Description: 1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl Methylcellulose
Description: 1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Sodium Phosphate
Description: 1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl Methylcellulose
Description: 1 drop 4 times daily for weeks 4-5
Study: NCT03267043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Description: Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Description: Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Established routine care provided on the NICU floor by specially trained health care professionals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Established routine care provided on the NICU floor by specially trained health care professionals.
Study: NCT04210362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshops on responsive caregiving
Description: Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshops on responsive caregiving
Description: Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshops on responsive caregiving
Description: Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
Study: NCT03879434

Intervention type: DEVICE
Intervention: Ostenil® Mini
Description: Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
Study: NCT03944954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo TMS Real
Description: Individuals will receive placebo and real TMS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marinol 10Mg Capsule TMS Real
Description: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marinol 10Mg Capsule TMS Real
Description: Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marinol 30Mg Capsule TMS Real
Description: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marinol 30Mg Capsule TMS Real
Description: Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
Study: NCT03557463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein
Description: A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy protein
Description: A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
Study: NCT00594984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetuximab
Description: IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: IV solution, IV, Q3W, 350 mg/m2, until progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: IV solution, IV, Q3W, 350 mg/m2, until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivanib
Description: Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brivanib
Description: Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brivanib Placebo
Description: Oral, tablet, QD, until progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brivanib Placebo
Description: Oral, tablet, QD, until progression
Study: NCT03223246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional teaching
Description: A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
Study: NCT03077750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP-245 Topical Gel
Description: Topical application BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Control With No Active Pharmaceutical Ingredients
Study: NCT02104713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic (MSC's) Application to the Burn Wounds
Description: Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose~1. Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.~2. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.~3. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.~4. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.~Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart.
Study: NCT01935271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muscle Armor Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01965496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: A injection administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: A injection administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: A injection administered subcutaneously
Study: NCT03551054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy for Two, Healthy for You
Description: Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Study: NCT01733602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Study: NCT03932721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab 140 MG/ML
Description: Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
Study: NCT00248989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: 3.0 ml of 0.3% DHEA cream applied on the skin twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 3.0 ml of placebo cream applied on the skin twice daily.
Study: NCT02603419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.